Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)

General Information of Drug (ID: DR0799)
Drug Name
Halofantrine
Synonyms
Halfan; Halofantrina; Halofantrina [INN-Spanish]; Halofantrine; Halofantrine (INN); Halofantrine HCl; Halofantrine [USAN]; Halofantrinum; Halofantrinum [INN-Latin]; R7ADS21FSN; dl-WR 171669; 3-(Dibutylamino)-1-(1,3-dichlor-6-(trifluormethyl)-9-phenanthryl)propanol; 3-(Dibutylamino)-1-(1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl)propan-1-ol; 3-(dibutylamino)-1-[1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl]propan-1-ol; 69756-53-2; MLS002154111; FOHHNHSLJDZUGQ-UHFFFAOYSA-N; UNII-R7ADS21FSN
Indication Malaria [ICD11: 1F40] Approved [1]
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 500.4 Topological Polar Surface Area 23.5
Heavy Atom Count 33 Rotatable Bond Count 10
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 5
Cross-matching ID
PubChem CID
37393
PubChem SID
9836 ; 603092 ; 4441467 ; 7979519 ; 8174993 ; 11406986 ; 11467059 ; 11468179 ; 11486828 ; 14859927 ; 34678697 ; 46506753 ; 47572921 ; 47572922 ; 47869196 ; 48317942 ; 48416078 ; 49699380 ; 50070734 ; 50123958 ; 77799953 ; 87245098 ; 92719358 ; 96024726 ; 103305814 ; 103994306 ; 104326444 ; 117505175 ; 125356362 ; 126424569 ; 126620878 ; 126653035 ; 126670922 ; 127875900 ; 134338227 ; 135029301 ; 135329562 ; 137251553 ; 152047097 ; 160643701 ; 160964551 ; 162178795 ; 163414203 ; 164786759 ; 172883008 ; 174006943 ; 179117060 ; 184545611 ; 196110120 ; 223400586
ChEBI ID
CHEBI:94392
CAS Number
69756-53-2
TTD Drug ID
D07MVK
Formula
C26H30Cl2F3NO
Canonical SMILES
CCCCN(CCCC)CCC(C1=C2C=CC(=CC2=C3C=C(C=C(C3=C1)Cl)Cl)C(F)(F)F)O
InChI
1S/C26H30Cl2F3NO/c1-3-5-10-32(11-6-4-2)12-9-25(33)23-16-22-21(14-18(27)15-24(22)28)20-13-17(26(29,30)31)7-8-19(20)23/h7-8,13-16,25,33H,3-6,9-12H2,1-2H3
InChIKey
FOHHNHSLJDZUGQ-UHFFFAOYSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
N-debutylhalofantrine DM004720
115076
Oxidation - N-debutylation 1 [2]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR005071 Halofantrine N-debutylhalofantrine Oxidation - N-debutylation CYP3A4 ... [2]
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Cytochrome P450 2C8 (CYP2C8) DME0018 Homo sapiens
CP2C8_HUMAN
1.14.14.1
[2]
Cytochrome P450 2D6 (CYP2D6) DME0009 Homo sapiens
CP2D6_HUMAN
1.14.14.1
[3]
Cytochrome P450 3A4 (CYP3A4) DME0001 Homo sapiens
CP3A4_HUMAN
1.14.14.55
[4]
Cytochrome P450 3A5 (CYP3A5) DME0012 Homo sapiens
CP3A5_HUMAN
1.14.14.1
[2]
References
1 Halofantrine was approved by FDA. The 2020 official website of the U.S. Food and Drug Administration.
2 Halofantrine metabolism in microsomes in man: major role of CYP 3A4 and CYP 3A5. J Pharm Pharmacol. 1999 Apr;51(4):419-26.
3 Halofantrine and chloroquine inhibit CYP2D6 activity in healthy Zambians. Br J Clin Pharmacol. 1998 Mar;45(3):315-7.
4 Pharmacokinetic and pharmacodynamic interaction between grapefruit juice and halofantrine. Clin Pharmacol Ther. 2002 Nov;72(5):514-23.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.